Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative.
about
In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's DiseaseThe oligomeric states of the purified sigma-1 receptor are stabilized by ligands.The sigma-1 receptor chaperone as an inter-organelle signaling modulatorMitochondrial protection by the mixed muscarinic/σ1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Aβ25-35 peptide-injected mice, a nontransgenic Alzheimer's disease model.Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism.The effects of sigma (σ1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice.Role of the Sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS)The sigma-1 receptors are present in monomeric and oligomeric forms in living cells in the presence and absence of ligandsThe sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements.Nootropics with potential to (re)build neuroarchitecture.Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.Selective sigma-1 receptor antagonists for the treatment of pain.Investigational sigma-1 receptor antagonists for the treatment of pain.Role of Sigma-1 Receptor in Cocaine Abuse and Neurodegenerative Disease.New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with σ-1 agonism and β-secretase inhibition.Role of σ1 Receptors in Learning and Memory and Alzheimer's Disease-Type Dementia.Sigma-1 (σ1) Receptor in Memory and Neurodegenerative Diseases.Emerging amyloid and tau targeting treatments for Alzheimer's disease.Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease.Sigma-1 Receptor Agonists Induce Oxidative Stress in Mitochondria and Enhance Complex I Activity in Physiological Condition but Protect Against Pathological Oxidative Stress.In vivo and ex vivo analyses of amyloid toxicity in the Tc1 mouse model of Down syndrome.Altered sigma-1 receptor expression in two animal models of cognitive impairment.Systolic blood pressure as a potential target of sigma-1 receptor agonist therapy.Sigma-1 Receptor in Motoneuron Disease.Neuroprotective effect of a new photobiomodulation technique against Aβ25-35 peptide-induced toxicity in mice: Novel hypothesis for therapeutic approach of Alzheimer's disease suggested.
P2860
Q28830911-E7CD85AF-135A-40F3-8F97-65B48B3C4F77Q33931257-9AAE2081-B1A3-462A-8888-E483DA7661B7Q34356970-6D59172F-1B7C-4D96-BAFE-16AE1841DD52Q34461389-5A10BB4D-24E2-4228-B6E2-85C0BFEDDCF5Q35154720-1B8F2381-AF6E-4B03-B474-47E21F972148Q35538511-97318CDC-912B-4EF6-B8B4-6E8A66C913FBQ35811244-BEDA4B26-C96C-42FD-9A45-EBFD6180E817Q35846559-89814E89-AC51-4241-8DDF-801E2AEAC355Q35856904-B487238A-B6D7-43FC-A509-870B41344291Q36639568-74C5B724-2798-49E2-8685-D9CBB247ED1FQ38022265-B6B07C2C-3D71-4106-B45E-B09FBF115712Q38235503-34805531-622C-4099-8178-6998D41EE3E8Q38513640-043D0B60-DBA0-4E0C-9E21-EF8C013645D2Q38743344-A15E71A9-A96B-4C93-B1F8-2E57C514DDFAQ38842928-4622FD4A-A905-4F63-9624-ABF2A529BC90Q38896662-B89304A8-CA9B-4813-AF66-F0CE724342DCQ39169781-1C60F556-5461-485B-8B32-FFDC9495E18BQ39296311-C77B1FA5-03CE-408B-A7ED-5C17F7B40644Q39296351-49DB8187-1B1F-4F38-A4E3-609194223830Q42020086-8BD67664-CD3F-4C7E-9E94-FA3AF85100BFQ44363046-1EE9F0FD-24DE-445A-9ACB-C06CA8C45DA6Q46263489-AA300B8C-6958-48D6-8AF8-FA8CE9EFE2A2Q47319838-F1B1F3A8-1BE3-4063-B218-AFEA74B176ADQ48026390-48E42A01-0DC5-4FF9-AA02-62A1D5B89729Q48242748-0C3AB140-A306-47D3-AC3B-7AAA92B123D9Q48258033-CE8BFF11-9612-42AA-84BF-17D3D4FB46FAQ55421100-F20F8BCF-BDBA-4732-BEAE-F1D4AD918CD2
P2860
Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Anti-amnesic and neuroprotecti ...... inotetrahydrofuran derivative.
@en
Anti-amnesic and neuroprotecti ...... inotetrahydrofuran derivative.
@nl
type
label
Anti-amnesic and neuroprotecti ...... inotetrahydrofuran derivative.
@en
Anti-amnesic and neuroprotecti ...... inotetrahydrofuran derivative.
@nl
prefLabel
Anti-amnesic and neuroprotecti ...... inotetrahydrofuran derivative.
@en
Anti-amnesic and neuroprotecti ...... inotetrahydrofuran derivative.
@nl
P2093
P2860
P356
P1476
Anti-amnesic and neuroprotecti ...... inotetrahydrofuran derivative.
@en
P2093
Alexandre Vamvakides
Emeline Keller
Julie Espallergues
Tangui Maurice
Vanessa Villard
P2860
P304
P356
10.1177/0269881110379286
P407
P577
2010-09-09T00:00:00Z